Inventiva (IVA)
(Delayed Data from NSDQ)
$2.68 USD
-0.05 (-1.65%)
Updated Jul 12, 2024 03:43 PM ET
After-Market: $2.73 +0.05 (1.87%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IVA 2.68 -0.05(-1.65%)
Will IVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IVA
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
Humana (HUM) Ups '23 Medicare Advantage Membership Growth View
IVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why You Should Retain Centene (CNC) in Your Portfolio Now
What You Need to Know From UnitedHealth's (UNH) Latest Outlook
Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?
Other News for IVA
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
Inventiva Shareholders Approve Key Resolutions
Inventiva Launches Share Repurchase Program